Feng Chi Biotech Corp.
Feng Chi Biotech Corp. engages in the wholesale and retail of medical equipment and precision instruments and biotechnology services in Taiwan and internationally. The company provides preimplantation genetic testing, prenatal testing, precision medicine, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services. It also distributes various geneti… Read more
Market Cap & Net Worth: Feng Chi Biotech Corp. (6744)
Feng Chi Biotech Corp. (TWO:6744) has a market capitalization of $6.98 Million (NT$231.00 Million) as of March 19, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #33780 globally and #1890 in its home market, demonstrating a -7.12% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Feng Chi Biotech Corp.'s stock price NT$15.00 by its total outstanding shares 15400000 (15.40 Million).
Feng Chi Biotech Corp. Market Cap History: 2026 to 2026
Feng Chi Biotech Corp.'s market capitalization history from 2026 to 2026. Data shows growth from $6.98 Million to $6.98 Million (0.00% CAGR).
Feng Chi Biotech Corp. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Feng Chi Biotech Corp.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 6744 by Market Capitalization
Companies near Feng Chi Biotech Corp. in the global market cap rankings as of March 19, 2026.
Key companies related to Feng Chi Biotech Corp. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Feng Chi Biotech Corp. Historical Marketcap From 2026 to 2026
Between 2026 and today, Feng Chi Biotech Corp.'s market cap moved from $6.98 Million to $ 6.98 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$6.98 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Feng Chi Biotech Corp. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.98 Million USD |
| MoneyControl | $6.98 Million USD |
| MarketWatch | $6.98 Million USD |
| marketcap.company | $6.98 Million USD |
| Reuters | $6.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.